Results 211 to 220 of about 5,637 (227)

HIV latency reversal agents: A potential path for functional cure?

European Journal of Medicinal Chemistry, 2021
Despite the advances in Human Immunodeficiency Virus (HIV) treatment, the cure for all HIV patients still poses a major challenge, which needs to be surpassed in the coming years. Among the strategies pursuing this aim, the 'kick-and-kill' approach, which involves the reactivation and elimination of a latent HIV reservoir that resides in some CD4+ T ...
Juliana Romano Lopes, Diego Eidy Chiba, Jean Leandro Dos Santos   +2 more
openaire   +2 more sources

Advances in structure-activity relationships of HDAC inhibitors as HIV latency-reversing agents

Expert Opinion on Drug Discovery
HIV-infected cells may rebound due to the existence of the silent HIV-infected memory CD4+ T cells (HIV latency). This HIV latency makes the disease almost incurable. In latency, the integrated proviral DNA of HIV is transcriptionally silenced partly due to the activity of histone deacetylases (HDACs).
Shovanlal Gayen, Tarun Jha, Sk Abdul Amin   +2 more
exaly   +3 more sources

High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing

Journal of Visualized Experiments, 2019
HIV remains incurable due to the existence of a reservoir of cells that harbors stable and latent form of the virus, which stays invisible to the immune system and is not targeted by the current antiretroviral therapy (cART). Transcription and splicing have been shown to reinforce HIV-1 latency in resting CD4+ T cells. Reversal of latency by the use of
Georges, Khoury, Damian F J, Purcell
openaire   +2 more sources

Discovery of Potent DAG-Lactone Derivatives as HIV Latency Reversing Agents

ACS Infectious Diseases
Toward human immunodeficiency virus type-1 (HIV-1) cure, cells latently infected with HIV-1 must be eliminated from people living with HIV-1. We previously developed a protein kinase C (PKC) activator, diacylglycerol (DAG)-lactone derivative 3, with high HIV-1 latency-reversing activity, based on YSE028 (2) as a lead compound and found that the ...
Takahiro Ishii, Takuya Kobayakawa, Kouki Matsuda, Kiyomi Nigorikawa, Peter Bolah, Airi Noborio, Kohei Tsuji, Nami Ohashi, Kazuhisa Yoshimura, Wataru Nomura, Hiroaki Mitsuya, Kenji Maeda, Hirokazu Tamamura   +12 more
openaire   +2 more sources

Human Immunodeficiency Virus and Latency Reversing Agents A Path to Cure?

2017
Background: Human immunodeficiency virus (HIV), as its namesake implies, is a virus that ultimately causes a deficient immune system that can lead to Acquired Immune Deficiency Syndrome (AIDS). Since the discovery of this cytopathic virus in 1983, there have been many scientific advances in regards to its identification and treatment.
openaire   +1 more source

THE CURRENT STATUS OF LATENCY REVERSING AGENTS

2019
info:eu-repo/semantics ...
openaire   +1 more source

Synthesis and Biological Evaluation of Simplified Ansellone Analogues with Lipophilic Side Chains as HIV Latency‐Reversing Agents

Chemistry - A European Journal, 2023
Kenichi Murai, Mitsuhiro Arisawa
exaly  

Potential HIV latency-reversing agents with STAT1-activating activity from the leaves of Wikstroemia chamaedaphne

Phytochemistry, 2022
Shifei Li
exaly  

HIV‐1 infection and latency‐reversing agents bryostatin‐1 and JQ1 disrupt amyloid beta homeostasis in human astrocytes

Glia, 2020
Michel J Tremblay, Alize Proust
exaly  

Creation of an Improved HIV Latency Model to Test Latency Reversal Agents

HIV is a retrovirus that infects CD4+ T-cells by integrating into the human genome. During productive infection, the virus enters a latent state in a small subset of cells. This allows HIV to persist and remain undetected by the immune system and current antiretroviral therapies (ART). While ART is highly effective at controlling HIV, it is not a
openaire   +1 more source